Intellia Therapeutics Inc (NASDAQ:NTLA)’s traded shares stood at 3.53 million during the latest session, with the company’s beta value hitting 1.77. At the last check today, the stock’s price was $16.30, to imply a decrease of -18.25% or -$3.64 in intraday trading. The NTLA share’s 52-week high remains $34.87, putting it -113.93% down since that peak but still an impressive -4.85% since price per share fell to its 52-week low of $17.09. The company has a valuation of $1.66B, with an average of 1.88 million shares in intraday trading volume over the past 10 days and average of 1.46 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Intellia Therapeutics Inc (NTLA), translating to a mean rating of 1.50. Of 13 analyst(s) looking at the stock, 0 analyst(s) give NTLA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 13 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
After registering a -18.25% downside in the latest session, Intellia Therapeutics Inc (NTLA) has traded red over the past five days. The 5-day price performance for the stock is -22.31%, and -21.24% over 30 days. With these gigs, the year-to-date price performance is -46.54%. Short interest in Intellia Therapeutics Inc (NASDAQ:NTLA) saw shorts transact 15.14 million shares and set a 10.32 days time to cover.
The extremes give us $24 and $252 for target low and target high price respectively. As such, NTLA has been trading -1446.01% off suggested target high and -47.24% from its likely low.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
Looking at statistics comparing Intellia Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Intellia Therapeutics Inc (NTLA) shares are -18.58% down over the last 6 months, with its year-to-date growth rate lower than industry average at -0.74% against 17.50%. Revenue is forecast to shrink -0.70% this quarter before jumping 2.70% for the next one. The rating firms project that company’s revenue will grow 46.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 21 analysts is 7.86M. Meanwhile, for the current quarter, a total of 21 analyst(s) estimate revenue growth to 8.63M.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -22.30% for the past 5-year period. While 2024 is set for a -0.13% return in earnings, projections for the next 5 years are at 30.00% annually.
NTLA Dividends
Intellia Therapeutics Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Intellia Therapeutics Inc insiders hold 1.21% of total outstanding shares, with institutional holders owning 87.42% of the shares at 88.48% float percentage. In total, 87.42% institutions holds shares in the company, led by ARK INVESTMENT MANAGEMENT LLC. As of 2024-06-30, the company held over 11.6 million shares (or 12.1419% of shares), all amounting to roughly $259.51 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 9.6 million shares, or about 10.0496% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $214.79 million.
We also have ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF as the top two Mutual Funds with the largest holdings of the Intellia Therapeutics Inc (NTLA) shares. Going by data provided on Sep 30, 2024, ARK ETF Tr-ARK Innovation ETF holds roughly 8.28 shares. This is just over 8.15% of the total shares, with a market valuation of $136.44 million. Data from the same date shows that the other fund manager holds a little less at 3.08, or 3.03% of the shares, all valued at about 50.68 million.
